technology+therapeutics

Bahrain has approved the Oxford-AstraZeneca COVID-19 vaccine for emergency use, state news agency BNA reported on Monday, citing the Gulf country’s National Health Regulatory Authority.

The CDC has predicted the U.K. variant could become the dominant strain of the disease in the U.S. as early as March.

Merck is discontinuing development of its two experimental Covid-19 vaccines after early clinical trials gave an inferior immune response.

Merck & Co. is discontinuing development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines.

Vaccination of priority groups with the Pfizer vaccine is expected to begin in late February at 80,000 doses per week.

The new shipment adds to an initial consignment of three million doses which Turkey received nearly a month ago.

Daily infections of the novel coronavirus in the UAE reached 3,529 on Thursday, the health ministry said, the highest in the Gulf Arab region.

Thailand has signed a deal with AstraZeneca to produce 26 million doses of its vaccine locally through the firm Siam Bioscience.

The ministry has designated about 250 spacious indoor gyms and theatres nationwide to vaccinate people with Pfizer and Moderna vaccines that require cold chain storage.

The vast majority of the production of the three most widely approved COVID vaccines, including the AstraZeneca drug, has so far been hoovered up by developed nations.

Supplying vaccines is one thing. Convincing people to take them is another.

Hungary’s drug regulator has given initial approval for use of Britain’s AstraZeneca and Russia’s Sputnik V vaccines against the coronavirus.

There has been growing criticism of “vaccine inequality” as developing countries struggle to secure supplies while wealthy nations begin inoculating populations.

Manufacturer-submitted versus payer-estimates: a review of incremental cost-effectiveness ratios for novel oncology drugs in Canada.

The story of seemingly promising drugs that did not pan out, including, most famously, the malaria drug hydroxychloroquine, has left many researchers wary.